Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph(+) acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Chandra, Joya, Tracy, Jeannette, Loegering, David, Flatten, Karen, Verstovsek, Srdan, Beran, Miloslav, Gorre, Mercedes, Estrov, Zeev, Donato, Nicholas, Talpaz, Moshe, Sawyers, Charles, Bhalla, Kapil, Karp, Judith, Sausville, Edward, Kaufmann, Scott H.
Formato: Artigo
Idioma:Inglês
Publicado: The American Society of Hematology 2006
Assuntos:
Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895739/
https://ncbi.nlm.nih.gov/pubmed/16291594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2966
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares